Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients

<div>Network meta-analysis and ranking of treatments for inducing response in anti-TNF-experienced CD patients via (a) SUCRA analysis and (b) league table graph. Odds ratios (ORs) with 95% confidence interval (CI) are reported. ADA = adalimumab; USTE = ustekinumab; VEDO = vedolizumab; NAT = natalizumab; PL = placebo.</div>

Gastroenterology Research and Practice

fig6

Figure 6

Figure 6: Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients 

Figure 6 | Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients 